Kalaris Therapeutics Inc (KLRS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
400 Connell Drive
Berkeley Heights, NJ 07922
United States of America (the)
Phone
+1 610 550 4220
Website
Sector
Healthcare
Industry
Biotechnology
Employees
20
First IPO Date
July 30, 2020
| Name | Title | Pay | Year Born |
| Andrew Oxtoby | President, Chief Executive Officer & Director | 882,039 | 1974 |
| Srinivas Akkaraju | Co-Founder & Director | 36,000 | 1968 |
| Michael Philip Dybbs | Co-Founder & Director | 39,000 | 1975 |
| Napoleone Ferrara | Independent Director & Co-Founder | 46,663 | 1957 |
| Matthew Feinsod | Chief Medical Officer | 665,368 | 1971 |
| Amy Vandekop | Interim Principal Accounting Officer & Corporate Controller | 0 | 1989 |
| Liisa Ann Bayko | Chief Financial Officer & Treasurer | 0 | 1971 |
| Jill E. Porter | Senior Vice President of CMC | 0 | N/A |
| Kristine Curtiss | Senior Vice President of Clinical | 0 | N/A |
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.